Incyte (INCY) Gains from Sales and Divestitures (2011 - 2019)
Incyte (INCY) reported Gains from Sales and Divestitures of $333334.0 for Q2 2019, up 25.0% on a YoY basis from $266667.0 in Q2 2018, and little changed quarter-over-quarter from $333334.0 in Q1 2019.
Incyte (INCY) Gains from Sales and Divestitures (2011 - 2019) Analysis & Trends
Incyte has reported Gains from Sales and Divestitures for 8 years, with the latest figure at $333334.0 in Q2 2019.
- For the quarter ending Q2 2019, Gains from Sales and Divestitures rose 25.0% year-over-year to $333334.0; the trailing twelve-month figure through Jun 2019 stood at $333334.0 (up 25.0% YoY), and the FY2018 full-year result was $266667.0, up 33.33% from the prior year.
- Gains from Sales and Divestitures for Q2 2019 stood at $333334.0, roughly flat from $333334.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $333334.0 in Q1 2019, with the low at $133333.0 in Q4 2015.
- Historically, Gains from Sales and Divestitures has averaged $233333.5 across 5 years, with a median of $233333.5 in 2017.
- Annual changes were most pronounced in 2015 — Gains from Sales and Divestitures tumbled 63.29% — and 2017, when it soared 50.0%.
- Incyte's Gains from Sales and Divestitures stood at $133333.0 in 2015, then changed by 0.0% to $133333.0 in 2016, then soared by 50.0% to $200000.0 in 2017, then soared by 33.33% to $266667.0 in 2018, then gained by 25.0% to $333334.0 in 2019.
- The last three Gains from Sales and Divestitures figures came in at $333334.0 (Q2 2019), $333334.0 (Q1 2019), and $266667.0 (Q4 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 333,334.00 |
| Jun 30, 2019 | 333,334.00 |
| Mar 31, 2019 | 333,334.00 |
| Mar 31, 2019 | 333,334.00 |
| Dec 31, 2018 | 266,667.00 |
| Dec 31, 2018 | 266,667.00 |
| Sep 30, 2018 | 266,667.00 |
| Sep 30, 2018 | 266,667.00 |
| Jun 30, 2018 | 266,667.00 |
| Jun 30, 2018 | 266,667.00 |
| Mar 31, 2018 | 266,667.00 |
| Mar 31, 2018 | 266,667.00 |
| Dec 31, 2017 | 200,000.00 |
| Dec 31, 2017 | 200,000.00 |
| Sep 30, 2017 | 200,000.00 |
| Sep 30, 2017 | 200,000.00 |
| Jun 30, 2017 | 200,000.00 |
| Jun 30, 2017 | 200,000.00 |
| Mar 31, 2017 | 200,000.00 |
| Mar 31, 2017 | 200,000.00 |